WST Research Note — The Multiple Faces CPI
West Pharmaceutical is growing with net cash, but CPI and Treasury yields will test whether its premium multiple can hold.
WST
WST Deep Coverage Review — Analysis as of August 11, 2026
West Pharmaceutical has durable growth and net cash, but a 35.34× forward multiple makes Treasury yields the immediate test.
WST Research Note — Good Quarter, Harder Proof
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.
WST Deep Coverage Review — Analysis as of August 3, 2026
West Pharmaceutical’s beat-and-raise supports the recovery thesis, but a heavy-volume reversal and oral-drug substitution risk keep confirmation incomplete.
WST Research Note — Growth Meets a Credibility Test
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.
WST Deep Coverage Review — Analysis as of July 27, 2026
West Pharmaceutical’s beat-and-raise supports the recovery thesis, but a heavy-volume reversal and oral-drug substitution risk keep confirmation incomplete.